ANDA 75466, held by Genpharm. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 75466 (Doxazosin Mesylate), held by Genpharm, was first approved by FDA on Oct 18, 2000, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2000 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Jun 5, 2007 | Supplement 10Labeling | Approved | None posted |
| Jun 27, 2005 | Supplement 6Labeling | Approved | None posted |
| Aug 30, 2002 | Supplement 5Labeling | Approved | None posted |
| Mar 13, 2002 | Supplement 4Manufacturing | Approved | None posted |
| Dec 21, 2001 | Supplement 3Manufacturing | Approved | None posted |
| Jul 24, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Apr 30, 2001 | Supplement 2Labeling | Approved | None posted |
| Oct 18, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters